Previous 10 | Next 10 |
Accumulating Preclinical Data Provide Further Support for Disease-Modifying Potential of Brain Penetrant Investigational Small Molecule Therapeutic, GT-02287 Results Presented at the Shaare Zedek Medical Center GBA-Parkinson’s Disease Symposium BETHESDA, Md., Se...
Biotechnology company Gain Therapeutics ( NASDAQ: GANX ) said COO Matthias Alder has been appointed CEO, effective immediately. Alder, who was also appointed to the company's board, succeeds Eric Richman. The size of the company's board is now increased to eight m...
BETHESDA, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sit...
Treatment with GT-02287 Resulted in a Significant Dose-Dependent Improvement of Cellular Lysosomal Health and Fine Motor Skills Results Presented at the International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting in Madrid, Spain BET...
Presenting Preclinical Data at 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain Upcoming Presentation on GBA-PD program at First International Symposium on GBA-PD in Jerusalem, Israel BETHESDA, Md., Sept. 08, 2022 (GLOBE...
BETHESDA, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sit...
B. Riley Securities downgraded the development stage biotech Gain Therapeutics, Inc. ( NASDAQ: GANX ) to Neutral from Buy on Friday, noting a material delay in the company's plans to seek regulatory clearance to start clinical trials for the Parkinson's disease lead candidate, G...
BETHESDA, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding site...
BETHESDA, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding site...
BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding site...
News, Short Squeeze, Breakout and More Instantly...
Gain Therapeutics Inc. Company Name:
GANX Stock Symbol:
NASDAQ Market:
Gain Therapeutics Inc. Website:
BETHESDA, Md. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announ...
GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson’s Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSW...